Sientra shares up after company releases 2021 revenue estimates
The Goleta-based breast implant manufacturer Sientra expects growth in the fourth quarter of 2021 and estimates its “highest-ever breast products yearly revenue” of up to $81 million for the full year, the company said Jan. 10.
Sientra reported that its preliminary unaudited revenue from operations for the fourth quarter of 2021 is expected to be in the range of $22 million to $23 million, representing growth of 23% to 29% compared to the same period in 2020.
Sientra said it also anticipated growth for full-year revenue. Preliminary unaudited revenue from operations for the full year 2021 is expected to be in the range of $80 million to $81 million, representing an increase of 46% to 47% compared to the full year 2020.
Sientra shares rose 9% on Jan. 10 after the release, closing at $3.38.
Sientra attributed the revenue growth to “continued strong demand for Sientra breast products and commercial execution.”
“Our strong fourth quarter results demonstrated the continued high level of execution our team has achieved throughout the year and represented our sixth consecutive quarter of record growth,” Sientra CEO Ron Menezes said in the company’s news release. “Importantly, we saw the impact of our commercial team’s exclusive focus on plastic surgeons as breast aesthetics remained the number one procedure in the U.S. aesthetics market in 2021.”
